Delving into the Latest Updates on Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Skin and Musculoskeletal Diseases

Respiratory Diseases

Small molecule drug

Liposomal Drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1
Liposomal Drug	1

Top 5 Target	Count

Tubulin	1

主要目的以Janssen-Cilag公司生产的盐酸多柔比星脂质体注射液（商品名：Caelyx®，规格：10mL:20mg）为参比制剂，按照生物等效性试验的有关规定，与常州金远药业制造有限公司生产的受试制剂盐酸多柔比星脂质体注射液（商品名：立幸；规格：10mL:20mg）进行体内药动学对比研究，考察多柔比星在乳腺癌患者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的研究受试制剂盐酸多柔比星脂质体注射液（规格：10mL:20mg）和参比制剂盐酸多柔比星脂质体注射液Caelyx®（规格：10mL:20mg）在乳腺癌患者中的安全性。

[Translation]

Main objective: Using doxorubicin hydrochloride liposome injection (trade name: Caelyx®, specification: 10mL:20mg) produced by Janssen-Cilag as the reference preparation, in accordance with the relevant provisions of the bioequivalence test, a comparative in vivo pharmacokinetics study was conducted with the test preparation doxorubicin hydrochloride liposome injection (trade name: Lixing; specification: 10mL:20mg) produced by Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. to investigate the pharmacokinetic behavior of doxorubicin in breast cancer patients and evaluate the bioequivalence of the two preparations. Secondary objective: To study the safety of the test preparation doxorubicin hydrochloride liposome injection (specification: 10mL:20mg) and the reference preparation doxorubicin hydrochloride liposome injection Caelyx® (specification: 10mL:20mg) in breast cancer patients.

Start Date01 Mar 2021

Sponsor / Collaborator

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

NCT02070523

/ Unknown statusPhase 3

Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells

To determine, compared with Daunorubicin(DNR), whether Pegylated liposomal doxorubicin (PLD) inducing higher complete remission (CR) rate, in untreated primary ALL adult patients with VDCLD regimen induction therapy. Second, to determine, compared with the DNR, whether chemotherapy containing PLD with a higher response rates and greater safety in adult ALL

Start Date01 Dec 2013

Sponsor / Collaborator

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

[+1]

CTR20181875

/ Not yet recruitingPhase 1

评价注射用多西他赛脂质体在恶性实体肿瘤患者中的安全性、耐受性和药代动力学特征的I期临床研究

[Translation] A phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of liposome docetaxel for injection in patients with malignant solid tumors

确定注射用多西他赛脂质体在恶性实体瘤患者中的安全性、耐受性，包括最大耐受剂量（MTD）和剂量限制性毒性（DLT）、药代动力学特征

[Translation]

To determine the safety, tolerability, including the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), and pharmacokinetic characteristics of liposome docetaxel for injection in patients with malignant solid tumors

Start Date-

Sponsor / Collaborator

Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

[+1]

100 Clinical Results associated with Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

Login to view more data

100 Deals associated with Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

Login to view more data

100 Translational Medicine associated with Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 Aug 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data